Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dexamethasone
KTX-1001 · 1 trial · 3 indications
Incidence of dose-limiting toxicity (DLTs), treatment-emergent adverse events (TEAEs), treatment-related AEs, and clinically significant changes in laboratory test results
| Arm | Type | Description |
|---|---|---|
| Cohort A (Single agent): KTX-1001 + dexamethasone | EXPERIMENTAL | Cohort A1 (single agent): KTX-1001 at RP2D1 + dex Cohort A2 (single agent): KTX-1001 at RP2D2 + dex |
| Cohort B (Mezigdomide): KTX-1001 + Mezigdomide + dex | EXPERIMENTAL | Cohort B1 (Mezigdomide): KTX-1001 at RP2D1 + Mezigdomide + dex Cohort B2 (Mezigdomide):: KTX-1001 at RP2D2 + Mezigdomide + dex |
| Cohort C (carfilzomib/KYPROLIS®): KTX-1001 + carfilzomib + dex | EXPERIMENTAL | Cohort C1 (carfilzomib/KYPROLIS®): KTX-1001 at RP2D1 + carfilzomib + dex Cohort C2 (carfilzomib/KYPROLIS®): KTX-1001 at RP2D2 + carfilzomib + dex |
| Cohort D (pomalidomide): KTX-1001 + pomalidomide + dex | EXPERIMENTAL | Cohort D (pomalidomide): KTX-1001 at RP2D2 + pomalidomide + dex |
| Name | Type | Description |
|---|---|---|
| Cohort A1 & A2: KTX-1001 | DRUG | KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly |
| Cohort B1 & B2: KTX-1001+Mezigdomide | DRUG | Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly |
| Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) | DRUG | Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle |
| Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid) | DRUG | Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle |
Key Inclusion Criteria for Dose-Expansion: * ≥ 18 years of age * ECOG score ≤ 1 * Multiple myeloma (as per IMWG) * Prior therapy for MM: Participants must have received at least 1 and up to 3 prior lines of therapy as defined by IMWG, and the following drug classes: PI, IMiD, and anti-CD38 antib...
Top 20 of 25 competitors
KTX-1001 is an investigational small molecule being studied for the treatment of multiple myeloma, including relapsed and refractory disease. It is being evaluated in a Phase 1 clinical trial in adults. It is not approved for any indication and remains in clinical development.
KTX-1001 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is the sponsor of the Phase 1 study evaluating KTX-1001 in multiple myeloma.
KTX-1001 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The single active trial is currently recruiting participants.
KTX-1001 is being studied in one active clinical trial, NCT05651932, titled A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma. The trial is recruiting and plans to enroll 165 participants across the United States, Canada, France, and Spain.
KTX-1001 is described as an MMSET inhibitor. MMSET is a molecular target in multiple myeloma, and the Phase 1 trial NCT05651932 is titled as a study of an MMSET inhibitor in patients with relapsed and refractory multiple myeloma.